


Nastorazepide

Cat. No.:	HY-17617		
CAS No.:	209219-38-5		
Molecular Formula:	C ₂₉ H ₃₆ N ₄ O ₅		
Molecular Weight:	520.62		
Target:	Cholecystokinin Receptor		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 32 mg/mL (61.47 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.9208 mL	9.6039 mL	19.2079 mL
	5 mM	0.3842 mL	1.9208 mL	3.8416 mL
	10 mM	0.1921 mL	0.9604 mL	1.9208 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.08 mg/mL (4.00 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.08 mg/mL (4.00 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Nastorazepide (Z-360), selective, orally available, 1,5-benzodiazepine derivative, is a gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antitumor activity^[1].

IC₅₀ & Target

CCKBR

REFERENCES

[1]. Kato H, et al. CCK-2/gastrin receptor signaling pathway is significant for gemcitabine-induced gene expression of VEGF in pancreatic carcinoma cells. Life Sci. 2011 Oct 24;89(17-18):603-8.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA